GEN-MKT-18-7897-A
Jul 8, 2016 | Biopharma, Blogs | 0 comments
The move to large molecules in Pharma is accelerating, offering unprecedented opportunities to improve human health and expand into new markets. But for those with extensive experience with small molecule bioanalysis, the shift to biologics can be challenging, from Sample Prep to Instrumentation and Software, to Methods and Training:
The challenges seem daunting, but SCIEX can help you overcome them with relative ease. Download a three-part infographic that addresses all three challenges and describes the solutions with links to useful reference material. The SCIEX BioBA Solution will get you up and running quickly and painlessly.Download Infographic >
Useful FAQ document to enable researchers to focus on their scientific discoveries and insights rather than the complexities of data management.
In today’s environment in which labs are under pressure to reduce operating costs, many will compare the cost of a service contract between third-party providers and the original equipment manufacturer (OEM). At first glance, going with a service contract from a third-party provider may seem like a smart financial move, but experience shows they can introduce risks that affect reliability and compliance.
We recently hosted a webinar focused on streamlining forensic toxicology workflows, featuring expert speakers Maria Sarkisian from the San Francisco Office of the Chief Medical Examiner (SFOCME) and Dr. Dick Paul Kloos from the Netherlands Forensic Institute (NFI). The webinar explored innovative LC-MS/MS strategies that help forensic labs improve efficiency. In this blog, we share highlights from the Q&A session, where our speakers addressed the audience’s questions and shared actionable insights for forensic laboratory professionals.
Posted by
You must be logged in to post a comment.
Share this post with your network